Menu
Search
|

Menu

Close
X

Global Blood Therapeutics Inc GBT.OQ (NASDAQ Stock Exchange Global Select Market)

61.50 USD
-- (--)
As of Feb 21
chart
Previous Close 61.50
Open --
Volume --
3m Avg Volume 261,144
Today’s High --
Today’s Low --
52 Week High 68.05
52 Week Low 23.55
Shares Outstanding (mil) 43.68
Market Capitalization (mil) 1,412.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.73 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.151
FY16
-2.466
FY15
-2.178
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.95
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-37.53
14.43
Return on Equity (TTM)
vs sector
-37.85
16.13

EXECUTIVE LEADERSHIP

Ted Love
President, Chief Executive Officer, Director, Since 2014
Salary: $479,375.00
Bonus: --
Jeffrey Farrow
Chief Financial Officer, Since 2016
Salary: $298,718.00
Bonus: --
Peter Radovich
Senior Vice President, Operations, Since 2016
Salary: --
Bonus: --
Hing Sham
Senior Vice President, Research, Since 2016
Salary: --
Bonus: --
Jung Choi
Chief Business and Strategy Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

400 E Jamie Ct Ste 101
SOUTH SAN FRANCISCO   CA   94080-6230

Phone: +1650.7417700

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

SPONSORED STORIES